HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects

Vaccine

Volumn 31, Issue 28, 2013, Pages 2914-2918

  Fabbiani, Massimiliano ^a   Sidella, Letizia ^a   Corbi, Maddalena ^a   Martucci, Rosa ^a   Sali, Michela ^a   Colafigli, Manuela ^a   Cauda, Roberto ^a   Delogu, Giovanni ^a   Sgambato, Alessandro ^a   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cellular immune response; HIV; Humoral immune response; Immunogenicity; Influenza; Vaccination

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TH1 CELL; VIRUS LOAD;

EID: 84884701342     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.033     Document Type: Article

References (17)

1. Fiore A.E., Uyeki T.M., Broder K., Euler G.L., Singleton J.A., Iskander J.K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
2. Beck C.R., McKenzie B.C., Hashim A.B., Harris R.C., UNIIC Study Group, Nguyen-Van-Tam J.S. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by aetiology. J Infect Dis 2012, 206:1250-1259.
3. Sheth A.N., Althoff K.N., Brooks J.T. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis 2011, 52:219-227.
4. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
5. Shahid Z., Kleppinger A., Gentleman B., Falsey A.R., McElhaney J.E. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010, 28:6145-6151.
6. Lagler H., Wenisch J.M., Tobudic S., Gualdoni G.A., Rödler S., Rasoul-Rockenschaub S., et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 2011, 29:6888-6893.
7. Manuel O., Pascual M., Hoschler K., Giulieri S., Alves D., Ellefsen K., et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011, 52:248-256.
8. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
9. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
10. Fabbiani M., Di Giambenedetto S., Sali M., Farina S., Sansonetti P., Tamburrini E., et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011, 29:2836-2839.
11. Viganò A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48:289-296.
12. Fritz S., Mossdorf E., Durovic B., Zenhaeusern G., Conen A., Steffen I., et al. Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. AIDS 2010, 24:2287-2289.
13. Agrati C., Gioia C., Castilletti C., Lapa D., Berno G., Puro V., et al. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. AIDS Res Hum Retroviruses 2012, 28:1606-1616.
14. Pariani E., Boschini A., Amendola A., Poletti R., Anselmi G., Begnini M., et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011, 29:9209-9213.
15. Crum-Cianflone N.F., Iverson E., Defang G., Blair P.J., Eberly L.E., Maguire J., et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011, 29:3183-3191.
16. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S., et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167-173.
17. Evison J., Farese S., Seitz M., Uehlinger D.E., Furrer H., Mühlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009, 48:1402-1412.